University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Public Health Resources

Public Health Resources

1-1-2021

IFNγ
IFN is a key link between obesity and Th1-mediated autoimmune
diseases
Heekyong R. Bae
Omixplus, LLC, bae@omixplus.com

Myung-Sook Choi
Kyungpook National University, mschoi@knu.ac.kr

Suntae Kim
Omixplus, LLC, skim@omixplus.com

Howard A. Young
National Cancer Institute, younghow@mail.nih.gov

M E. Gershwin
megershwin@ucdavis.edu

See next page for additional authors

Follow this and additional works at: https://digitalcommons.unl.edu/publichealthresources
Part of the Medicine and Health Sciences Commons

Bae, Heekyong R.; Choi, Myung-Sook; Kim, Suntae; Young, Howard A.; Gershwin, M E.; Jeon, Seon Min; and
Kwon, Eun Young, "IFNγ is a key link between obesity and Th1-mediated autoimmune diseases" (2021).
Public Health Resources. 568.
https://digitalcommons.unl.edu/publichealthresources/568

This Article is brought to you for free and open access by the Public Health Resources at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Public Health Resources
by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors
Heekyong R. Bae, Myung-Sook Choi, Suntae Kim, Howard A. Young, M E. Gershwin, Seon Min Jeon, and
Eun Young Kwon

This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
publichealthresources/568

International Journal of

Molecular Sciences
Article

IFNγ Is a Key Link between Obesity and Th1-Mediated
AutoImmune Diseases
Heekyong R. Bae 1,2,3,† , Myung-Sook Choi 3,† , Suntae Kim 1 , Howard A. Young 2 , M. Eric Gershwin 4 ,
Seon-Min Jeon 5, * and Eun-Young Kwon 3, *
1
2

3

4

5

*
†



Citation: Bae, H.R.; Choi, M.-S.; Kim,
S.; Young, H.A.; Gershwin, M.E.; Jeon,
S.-M.; Kwon, E.-Y. IFNγ Is a Key Link
between Obesity and Th1-Mediated
AutoImmune Diseases. Int. J. Mol. Sci.
2021, 22, 208. https://dx.doi.org/
10.3390/ijms22010208
Received: 27 November 2020
Accepted: 24 December 2020
Published: 28 December 2020

Omixplus, LLC., Gaithersburg, MD 20885, USA; bae@omixplus.com (H.R.B.); skim@omixplus.com (S.K.)
Laboratory of Cancer Immunometabolism, Cancer and Inflammation Program, Center for Cancer Research,
National Cancer Institute-Frederick, Frederick, MD 21701, USA; younghow@mail.nih.gov
Department of Food Science and Nutrition, Center for Food and Nutritional Genomics Research,
Kyungpook National University, Daegu 41566, Korea; mschoi@knu.ac.kr
Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis, Davis,
CA 95616, USA; megershwin@ucdavis.edu
R&D Center, APtechnologies Corp., Gyeonggi-do, Hwaseong-si 18469, Korea
Correspondence: smjeon111@gmail.com (S.-M.J.); eykwon@knu.ac.kr (E.-Y.K.); Tel.: +82-53-950-7936 (S.-M.J.);
+82-53-950-6231 (E.-Y.K.)
These authors contributed equally to this work.

Abstract: Obesity, a characteristic of metabolic syndrome, is also associated with chronic inflammation and the development of autoimmune diseases. However, the relationship between obesity
and autoimmune diseases remains to be investigated in depth. Here, we compared hepatic gene
expression profiles among high-fat diet (HFD) mice using the primary biliary cholangitis (PBC)
mouse model based on the chronic expression of interferon gamma (IFNγ) (ARE-Del-/- mice). The
top differentially expressed genes affected by upstream transcriptional regulators IFNγ, LPS, and
TNFα displayed an overlap in HFD and ARE-Del-/- mice, indicating that obesity-induced liver
inflammation may be dependent on signaling via IFNγ. The top pathways altered in HFD mice
were mostly involved in the innate immune responses, which overlapped with ARE-Del-/- mice. In
contrast, T cell-mediated signaling pathways were exclusively altered in ARE-Del-/- mice. We further
evaluated the therapeutic effect of luteolin, known as anti-inflammatory flavonoid, in HFD and AREDel-/- mice. Luteolin strongly suppressed the MHC I and II antigen presentation pathways, which
were highly activated in both HFD and ARE-Del-/- mice. Conversely, luteolin increased metabolic
processes of fatty acid oxidation and oxidative phosphorylation in the liver, which were suppressed
in ARE-Del-/- mice. Luteolin also strongly induced PPAR signaling, which was downregulated
in HFD and ARE-Del-/- mice. Using human GWAS data, we characterized the genetic interaction
between significant obesity-related genes and IFNγ signaling and demonstrated that IFNγ is crucial
for obesity-mediated inflammatory responses. Collectively, this study improves our mechanistic
understanding of the relationship between obesity and autoimmune diseases. Furthermore, it provides new methodological insights into how immune network-based analyses effectively integrate
RNA-seq and microarray data.
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1. Introduction
Interferon gamma (IFNγ), the only characterized Type II interferon, is an inflammation
modulator regulating both pro- and anti-inflammatory responses. IFNγ is predominantly
produced by natural killer (NK) cells and natural killer T cells during the innate immune
response and by CD4+ T helper (Th1) cells and CD8+ cytotoxic T cells in the humoral
immune response. Furthermore, emerging evidence shows that other cell types, including
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macrophages, dendritic cells, and neutrophils, also produce IFNγ in a context-dependent
manner. IFNγ expression is critical for the initial host innate immune response and is
also essential to mount an adaptive immune response. Several reports have shown that
serum IFNγ is increased in patients with autoimmune diseases such as systemic lupus
erythematosus (SLE) and rheumatoid arthritis (RA) [1]. Corresponding to this data, IFNG
polymorphisms are associated with susceptibility to these diseases in patient cohorts [2,3].
Aberrant IFNγ expression was observed in other autoimmune disease murine models,
including experimental autoimmune encephalomyelitis and collagen-induced arthritis, in
both protective and detrimental roles [4].
Primary biliary cholangitis (PBC) is an autoimmune disease of the liver, predominantly
affecting middle-aged women but having a worse prognosis in men, which eventually
leads to liver failure [5]. PBC is characterized by progressive destruction of the bile ducts
in the liver, caused by autoreactive T cell-mediated self-attack on the biliary epithelial cells.
Incidence of PBC is gradually increasing worldwide, but there is as of yet no cure, leaving
liver transplantation as the sole treatment option in later stages. Previously, we reported
that a mouse model (ARE-Del-/- ), characterized by chronic expression of IFNγ, has strong
serological, and pathological phenotypes of PBC [6]. These include portal inflammation,
bile duct damage, positive anti-mitochondrial antibodies (AMAs, >95% positive in patients
with PBC), and increased serum bile acid with disease progression. This mouse model
was noted to be a powerful new research tool, as it strongly reflected clinical features of
female-prevalent autoimmune diseases [7,8]. ARE-Del-/- mice with chronic low expression
of IFNγ are generated by genetic deletion of the AU-rich element (ARE) in the 3’-UTR
region of IFNG. Given that PBC is thought to be a Th1-mediated autoimmune disease, our
findings support a primary role for IFNγ in the development of PBC.
Over the last few decades, obesity has become a major research interest due to its dramatic increase worldwide and the clinical and economic burden of obesity-related diseases.
Obesity-related inflammatory responses are associated with adipokines secreted by adipose
tissue, which function as hormones and cytokines to modulate inflammatory responses and
metabolic processes [9]. Recent emerging views indicated a potential relationship between
obesity and major autoimmune diseases such as SLE, RA, multiple sclerosis, and type
1 diabetes [10–13]. However, the underlying mechanisms that connect these conditions
remain to be elucidated. Leptin is an adipokine, primarily secreted by adipocytes, and
is considered a key regulator of inflammatory responses and metabolic processes [14].
Here we characterize the central pathogenic role of IFNγ in HFD-induced inflammatory
responses. Our data provide new insight into the mechanism of the interaction between
IFNγ and leptin signaling, which furthers our understanding of the relationship between
obesity and the development of Th1-mediated autoimmune diseases.
2. Results
2.1. Comparison of Top Regulators and Pathways between High-Fat Diet (HFD) and ARE-Del-/- mice
We compared the top upstream transcriptional regulators in both HFD and AREDel-/- mice. The top upstream regulators in HFD mice were determined to be IFNγ
(p = 9.19 × 10−24 ), TLR4 (p = 5.43 × 10−23 ), and TNF (p = 1.04 × 10−21 ) (Table 1). These
transcriptional regulators overlapped with those in ARE-Del-/- mice, as previously reported [6]. These data indicate that IFNγ signaling plays a critical role in HFD-induced
inflammatory responses. We further characterized top pathways altered in HFD mice, and
compared these pathways in ARE-Del-/- mice (Figure 1). The top 20 altered pathways in
ARE-Del-/- mice are listed in Figure 1A. The top differential pathways in HFD mice were
aligned and compared with those in ARE-Del-/- mice (Figure 1B). It was notable that T
cell-mediated responses were mostly detected in ARE-Del-/- mice, but not in HFD mice. In
the same way, we aligned the altered pathways in ARE-Del-/- mice according to the top
20 canonical pathways in HFD mice (Figure 1C,D). These data show that innate immune
responses were among the top pathways altered in HFD mice (Figure 1C), which were also
strongly activated in ARE-Del-/- mice (Figure 1D). Overall, there were robust similarities
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among the top upstream regulators and pathways between HFD and ARE-Del-/- mice,
were among
top pathways
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HFD
mice (Figure 1C),
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also
strongly
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thatthe
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can aggravate
pathological
development
PBC.
Importantly,
-/- mice (Figure 1D). Overall, there were robust similarities among the
in ARE-Del
HFDactivated
mice display
IFNγ-induced
early innate inflammatory responses, whereas ARE-Del-/upstream regulators and pathways between HFD and ARE-Del-/- mice, suggesting that
micetop
display
more advanced adaptive immune responses.

a HFD can aggravate the pathological development of PBC. Importantly, HFD mice display IFNγ-induced early innate inflammatory responses, whereas ARE-Del-/- mice display
Tablemore
1. The
top upstream
transcriptional
regulators in high-fat-diet mice, determined by the
advanced
adaptive immune
responses.

Ingenuity® Knowledge Base.

Table 1. The top upstream transcriptional regulators in high-fat-diet mice, determined by the Ingenuity® Knowledge Base.
Top Regulators
p-Value

9.19 × 10−24
Top Regulators
p-ValueIFNγ
TLR4
5.43 × 10−23
IFNγ
9.19 × 10−24
−23
1.04 × 10−21
TLR4
5.43 × 10 TNF
−21
TNF
10 the overlap between the dataset genes and genes
Fisher’s exact test 3p-values are
calculated 1.04
based× on
1
21
32

Fisher’sby
exact
test p-values transcriptional
are calculated based
on the overlap between the dataset genes and
regulated
the appropriate
regulator.
genes regulated by the appropriate transcriptional regulator.

-/- mice. (A)
-/- mice. (A) The
Figure
1. The comparison
altered pathways
between high-fat-diet
andThe
ARE-Del
Figure 1. The comparison of altered
pathways
between of
high-fat-diet
and ARE-Del
top 20
altered pathways
pathways specifically intop 20 altered pathways in ARE-Del-/- mice. Yellow marks represent
-/-/in ARE-Del mice. Yellow marks represent pathways
specifically
increased
in
ARE-Del
mice
compared
tohigh-fat-diet
creased in ARE-Del-/- mice compared tohigh-fat-diet mice ; (B) Overlapping pathways of high-fatmice; (B) Overlapping pathwaysdiet
of high-fat-diet
mice
were
aligned
with
those
in
(A);
(C)
The
top
20
altered
pathways in
mice were aligned with those in (A); (C) The top 20 altered pathways in high-fat-diet mice;
high-fat-diet mice; (D) Overlapping pathways of ARE-Del-/- mice were aligned with those in (C). Ratio (bottom y-axis, red
line) refers to the number of genes from the dataset divided by the total number of genes that make up that pathway from
within the ingenuity pathway analysis (IPA) knowledge base. The -log of the p-value (top y-axis, bar) was calculated by
Fisher’s exact test.
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2.2. The Therapeutic Effect of Luteolin on the Early Development of PBC
In a previous study, luteolin improved insulin resistance and hepatic steatosis by
suppressing hepatic lipogenesis and lipid absorption in a HFD mouse model [15]. Given
that IFNγ-mediated immune responses play a primary role in HFD-induced inflammatory responses, we further characterized the immune responses in HFD mice by treating
these mice with luteolin. Luteolin is a natural flavonoid present in various fruits and
vegetables, and many studies have shown that it possesses anti-oxidant, anti-cancer, and
anti-inflammatory effects [16]. However, it is not yet understood how luteolin modulates
immune responses in terms of these therapeutic effects. In Table 2, we compared the top 20
altered pathways in HFD mice with those altered after luteolin treatment and ARE-Del-/mice. Although similar pathways were activated in HFD and ARE-Del-/- mice, luteolin
downregulated these pathways in HFD mice, implying that it may also suppress early
inflammatory responses in ARE-Del-/- mice.
Table 2. Suppressive effects of luteolin treatment on the top 20 altered pathways in high-fat-diet mice.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Top 20 Canonical Pathways in HFD Mice

HFD

ARE

Lut

Fcγ Receptor-Mediated Phagocytosis in Macrophages and Monocytes
Leukocyte Extravasation Signaling
Phagosome Formation
Granulocyte Adhesion and Diapedesis
Natural Killer Cell Signaling
IL-10 Signaling
Dendritic Cell Maturation
Atherosclerosis Signaling
Production of Nitric Oxide and Reactive Oxygen Species in Macrophages
PI3K Signaling in B Lymphocytes
TREM1 Signaling
Hepatic Fibrosis/Hepatic Stellate Cell Activation
Altered T cell and B cell Signaling in Rheumatoid Arthritis
Agranulocyte Adhesion and Diapedesis
Communication between Innate and Adaptive Immune Cells
CCR5 Signaling in Macrophages
Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses
Toll-like Receptor Signaling
Role of NFAT in Regulation of the Immune Response
B Cell Receptor Signaling

up
up
up
up
up
up
up
up
up
up
up
up
up
up
up
up
up
up
up
up

up
up
up
up
up
up
up
up
up
up
up
up
up
up
up
up
up
up
up
up

down
down
down
down
down
down
down
down
down
down
down
down
down
down
down
down
down
down

HFD, high-fat-diet mice; ARE, ARE-Del-/- mice; Lut, HFD with luteolin treatment.

2.3. Luteolin Modulates Antigen Presentation and Energy Metabolic Pathways
We previously reported that chronic expression of IFNγ activated the antigen presentation pathway in the liver [6]. This indicates that early inflammatory response in ARE-Del-/mice also had a strong induction of antigen presentation pathways, including increased
expression of MHC class I and II molecules. Consistent with this, gene set enrichment analysis (GSEA) profiles showed that HFD mice displayed positive regulation of MHC I and II
expression, while these expressions were suppressed upon luteolin treatment (Figure 2A).
Given that IFNγ is critical for antigen presentation in innate immune responses, and IFNγ
is also important for primary inflammatory signaling in HFD mice, this result suggests that
luteolin ameliorates inflammatory responses in the innate immune system, possibly via
suppression of IFNγ signaling pathway.
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pro- as well as anti-inflammatory responses [17,18]. HFD mice displayed negative regulation of the FAO and Oxphos pathways as determined by hepatic gene expression (Figure
2B). At the same time, FAO and Oxphos pathways were strongly induced in HFD mice
upon luteolin treatment. Even though these data represented changes in global hepatic
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gene expression in HFD mice, important information can still be gleaned about the potential effects of luteolin on the metabolic switch in immune cells.

Figure 2.
2. Gene
Gene Set
SetEnrichment
EnrichmentAnalysis
Analysis(GSEA)
(GSEA)ofofantigen
antigenpresentation
presentation
pathways
(A)
and
metaFigure
pathways
(A)
and
metabolic
bolic pathways
in high-fat-diet
mice with/without
luteolin
treatment.
(A) Expression
of MHC-I
pathways
(B) in (B)
high-fat-diet
mice with/without
luteolin
treatment.
(A) Expression
of MHC-I
and
and MHC-II gene sets in high-fat-diet mice with and without luteolin treatment; (B) Expression of
MHC-II gene sets in high-fat-diet mice with and without luteolin treatment; (B) Expression of FAO
FAO and Oxphos gene sets in high-fat-diet mice with and without luteolin treatment. FDR, false
and Oxphos gene sets in high-fat-diet mice with and without luteolin treatment. FDR, false discovery
discovery rate; FWER, family wise error rate; NES, normalized enrichment scores.
rate; FWER, family wise error rate; NES, normalized enrichment scores.

We also analyzed changes in metabolic pathways, such as fatty acid oxidation (FAO)
and oxidative phosphorylation (Oxphos). Emerging evidence suggests that immune cells
such as macrophages and dendritic cells switch metabolic pathways to modulate their proas well as anti-inflammatory responses [17,18]. HFD mice displayed negative regulation
of the FAO and Oxphos pathways as determined by hepatic gene expression (Figure 2B).
At the same time, FAO and Oxphos pathways were strongly induced in HFD mice upon
luteolin treatment. Even though these data represented changes in global hepatic gene
expression in HFD mice, important information can still be gleaned about the potential
effects of luteolin on the metabolic switch in immune cells.
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There were 269 upregulated genes in the liver of HFD mice, of which macrophages
2.4. HFD Dysregulates Macrophage Function, Possibly via the IFNγ Signaling Pathway
are one of the top cell phenotypes, according to the ARCHS4 database and Mouse Genome
There were 269 upregulated genes in the liver of HFD mice, of which macrophages
Informatics (MGI) database
resources, and as characterized by Enrichr pathway analysis
are one of the top cell phenotypes, according to the ARCHS4 database and Mouse Genome
(Figure 3A). Other characterized
cell
phenotypes
included
innate immune
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Informatics (MGI)
database
resources,
and as characterized
by Enrichr
dendritic cells, plasmacytoid
dendritic
cells,
and
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(Figure
3B).
These
data
sup-such as
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dendritic
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(Figure
data support the previous conclusion
that
HFD-induced
inflammation
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in 3B).
the These
innate
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the
previous
conclusion
that
HFD-induced
inflammation
is
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in
the
immune response, particularly via macrophage immunomodulation. Notably, the HFD innate
immune
response, particularly
macrophage
immunomodulation.
the HFD
increased dysregulated
macrophage
function, via
including
abnormal
macrophageNotably,
physiolincreased dysregulated macrophage function, including abnormal macrophage physiology and impaired macrophage phagocytosis according to the MGI database resources
ogy and impaired macrophage phagocytosis according to the MGI database resources
(Figure 3C). This is consistent
previouswith
report
IFNγreport
altered
(Figure 3C).with
This our
is consistent
our that
previous
thatmacrophage
IFNγ alteredfuncmacrophage
tion and impaired autophagy
[19],
which
can
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to
impaired
macrophage
function and impaired autophagy [19], which can lead to impairedphagocytosis.
macrophage phagocyThese data reveal that
IFNγ
in HFDpathway
mice plays
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These
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the IFNγ signaling
in HFD
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Figureof3.upregulated
Pathway analysis
of upregulated
in the
liver(A)
of HFD
mice. (A)
Abnormal macroFigure 3. Pathway analysis
genes
in the liver genes
of HFD
mice.
Abnormal
macrophage
phage function predicted by pathway analysis based on ARCH4 and MGI phenotypes databases;
function predicted by (B)
pathway
basedphenotypes
on ARCH4
and MGI
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databases;
(B) The
The top analysis
10 upregulated
according
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ARCH4 database;
(C) A cluster
graph of
top 10 upregulated phenotypes
according
the ARCH4
database;
(C) Aand
cluster
graph
of genephagocygene expression
profiles oftoabnormal
macrophage
physiology
impaired
macrophage
tosis in the MGI
phenotypes
database. and impaired macrophage phagocytosis in
expression profiles of abnormal
macrophage
physiology
the MGI phenotypes database.

2.5. Luteolin Activated Nuclear Receptor (NR) Signaling Pathways, Including LXR, RXR, and
PPAR
2.5. Luteolin Activated
Nuclear Receptor (NR) Signaling Pathways, Including LXR, RXR, and

PPAR
Given that NR signaling, including the LXR, RXR, and PPAR signaling pathways,
were suppressed in ARE-Del-/- mice [19], we further analyzed 64 downregulated genes in
the liver of HFD mice. The top pathways associated with these significantly downregulated
genes were defined according to the Chromatin Immunoprecipitation (ChIP) Enrichment
Analysis (ChEA; 2016) and Mouse Gene Atlas databases (Figure 4A). Interestingly, our
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data indicated that brown adipocyte gene expression was significantly downregulated
ingly,
our data indicated that brown adipocyte gene expression was significantly down(p = 1.9 ×regulated
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Figure 4. Pathway analysis of downregulated genes in the liver of HFD mice. (A) Downregulated

Figure 4. Pathway analysis of downregulated genes in the liver of HFD mice. (A) Downregulated
NR signaling pathways and genes associated brown adipose tissue based on ChEA and Mouse
NR signaling
and genes
associated
brown
adipose tissue
based
on ChEA and
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database;
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database; (C) GSEA profiles of PPAR signaling in HFD with and without luteolin
treatment.
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To characterize the genetic interaction between IFNγ and obesity-related genes, we
identified the 53 most significant variants (p ≤ 1 × 10−5), selected by the National Human
2.6. Interaction between IFNγ and Obesity-Related Genes
Genome Research Institute GWAS catalog. Among these genes, 47 have known direct or
To characterize the genetic interaction between IFNγ and obesity-related genes, we
−5 ), selected
indirect interactions
IFNγ
(Figure
5). Using
explorative
analysis
identified the with
53 most
significant
variants
(p ≤ 1the
× 10pathway
by the National
Humantool of
ingenuityGenome
pathway
analysis
(IPA)
software,
we identified
two
TNFA
and
Research
Institute
GWAS
catalog. Among
these genes,
47 genes,
have known
direct
or UBC
indirect
interactions
with
IFNγ
(Figure
5).
Using
the
pathway
explorative
analysis
tool
(Ubiquitin C), that maximize the connection between obesity-related genes and IFNγ. As
ingenuity
pathway
analysiswas
(IPA)one
software,
identified two
genes, TNFA and
UBC
shown in ofTable
1, TNFα
signaling
of topweupstream
transcriptional
regulators
in
(Ubiquitin C), that maximize the connection between obesity-related genes and IFNγ. As
the liver of
HFD
mice,
implying
that
IFNγand
TNF-mediated
inflammatory
responses
shown in Table 1, TNFα signaling was one of top upstream transcriptional regulators in
are majorthe
events
obesity-associated
chronic
Although
the functional
liver in
of HFD
mice, implying that
IFNγ- inflammation.
and TNF-mediated
inflammatory
responses role
arenot
major
events
in characterized
obesity-associated
chronic inflammation.
Although
functional
role
of UBC has
been
well
because
deletion of this
gene the
results
in embryonic
of
UBC
has
not
been
well
characterized
because
deletion
of
this
gene
results
in
embryonic
lethality due to its requirement for fetal liver development [21], the genetic deletion of
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Figure 5. Interconnected
networks between
IFNγ
and the most
significant
obesity-related
variants.
The most significant
Figure 5.gene
Interconnected
gene
networks
between
IFNγ
and the most
significant
obesity-related
55 variants were selected by the National Human Genome Research Institute GWAS catalog (p ≤ 1 × 10−5 ). TNFA and UBC
variants. The most significant 55 variants were selected by the National Human Genome Research
were identified by explorative analysis in IPA. Solid and −5
dashed lines indicate direct and indirect interactions, respectively.

Institute GWAS catalog (p ≤ 1 × 10 ). TNFA and UBC were identified by explorative analysis in
IPA. Solid and dashed lines indicate direct and indirect interactions, respectively.

3. Discussion
Excessive lipid accumulation in obesity has been linked to the release of detrimental
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3. Discussion
Excessive lipid accumulation in obesity has been linked to the release of detrimental
cytokines and chemokines that result in metabolic dysregulation. In obese humans with a
body mass index over 30, pro- and anti-inflammatory cytokines are upregulated, including
IL-5, IL-10, IL-12, IL-13, IFNγ, and TNFα [23]. Although obesity is known to have a component of low-grade, systemic inflammation, the relationship between obesity-associated
inflammation and autoimmune diseases remains to be elucidated. The mouse model
of autoimmune diseases used here displays chronic expression of IFNγ via the genetic
modification of the AU-rich element in the 30 -UTR of IFNG mRNA [24]. Notably, the top
upregulated transcriptional regulators in the liver of both HFD and ARE-Del-/- mice displayed an overlap, suggesting that IFNγ may be a primary cytokine in obesity-associated
inflammatory responses. These data also imply that the chronic expression of IFNγ in
obesity aggravates Th1-mediated autoimmune diseases. In this analysis, we compared
male HFD mice to female ARE-Del-/- mice. As reported previously, ARE-Del-/- mice
have female-biased pathological and serological phenotypes of PBC, and the prevalence in
females is a hallmark of major autoimmune diseases [25]. Considering that female mice
have a strong sensitivity to Th1-mediated inflammatory responses, we hypothesized that
female HFD mice would have more interesting pathological phenotypes compared to male
HFD mice. Collectively, our data support the primary role for IFNγ in linking obesity to
the development of autoimmune diseases.
There are remarkable differences in the upregulated inflammatory responses between
HFD and ARE-Del-/- mice, even though IFNγ is a common primary regulator in these conditions. HFD mice display early IFNγ-mediated innate inflammatory responses, whereas
ARE-Del-/- mice have greater adaptive immune responses, such as activation of T helper
cells and associated signaling pathways. In ARE-Del-/- mice, the low but chronic expression of IFNγ induced distinct pathological phenotypes similar to PBC [6], and early
IFNγ-mediated inflammation was involved in the activation of the innate immune system, triggering antigen presentation signaling pathways [6]. In HFD mice, the low but
chronic expression of IFNγ may stimulate early innate immune responses similar to those
in ARE-Del-/- mice, depending on the local and systemic levels of IFNγ. As previously
reported, beyond a certain threshold, IFNγ breaks the immune tolerance which induces
autoreactive B and T cells to attack self-epitopes in specific cells and organs, leading to
autoimmune diseases [19]. Therefore, obesity-induced IFNγ signaling can be aggravated
by infectious, genetic and environmental factors to break this immune tolerance barrier in
the host immune system.
In adipocytes, IFNγ inhibits PPARγ-mediated gene expression by not only suppressing protein synthesis, but also increasing protein degradation of PPARγ [26]. The polyubiquitination of PPARγ is regulated by IFNγ pathways dependent on serine phosphorylation
of PPARγ. Therefore, IFNγ regulates PPARγ expression, while PPARγ also directly regulates IFNγ expression. The PPARγ agonist thiazolidinedione rosiglitazone (Ro) suppresses
expression of IFNγ target genes in macrophages [27]. Conversely, the PPARγ antagonist
GW9662 increases lymphocyte IFNγ expression, and PPARγ ligands modulate expression
at the IFNγ promotor, indicating that PPARγ negatively regulates the IFNγ promoter [28].
Collectively, these data suggest that PPARγ and IFNγ reciprocally suppress their activities, which may be a central regulatory node to modulate lipid metabolic pathways and
Th1-mediated inflammatory responses.
Obesity increases the infiltration of macrophage in adipose tissue, and induces secretion of several inflammatory mediators [29]. Increased expression of IFNγ and TNFα
are classified as markers of pro-inflammatory (M1) rather than anti-inflammatory (M2)
polarization in macrophages [30]. Given that IFNγ and TNFα were determined to be
top transcriptional regulators in HFD mice, it is likely that M1 macrophages are strongly
activated in obesity. Metabolically, M2 macrophages are more dependent on oxidative phosphorylation, the dramatic switch to which results in phenotypic and functional changes
in macrophages [31]. Moreover, upregulated genes in HFD mice indicated activation of
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microphages as well as dysregulation of macrophage functions. Similar to this, chronic
expression of IFNγ in ARE-Del-/- mice induced abnormal macrophage function, such as
defective autophagy, which has been linked to dysregulated lipid metabolism through
altered NR signaling [19]. The macrophage is a primary cell type in the formation of most
granulomas, where immune cell aggregates form in response to chronic inflammatory stimuli such as Mycobacterium tuberculosis infection [32]. Considering that granuloma formation
is a pathophysiological phenotype in both PBC and ARE-Del-/- mice, these data suggest
that dysregulated lipid metabolism in macrophages via altered NR signaling pathways
may play a critical role in granuloma formation as well as obesity-associated pathology.
One of the most recognized adipokines, leptin, is a key molecule in the interplay
between energy metabolism homeostasis and metabolism-linked inflammatory responses.
Leptin is involved in the JAK/STAT pathway along with IFNγ, and acts synergistically with
IFNγ-mediated inflammatory responses [33]. In contrast, alternative p38, ERK, JNK, PKC,
and PI3K/AKT pathways overlap in signaling via both leptin and IFNγ receptors [34–37].
IFNγ binding to its specific receptor activates JAK1/JAK2, resulting in dimerization of
STAT1, which acts as a transcription factor to induce IFNγ response genes. In contrast, leptin binding to its receptor induces phosphorylation of JAK2, which subsequently activates
STAT3 via dimerization.
Given that JAK2 plays a critical role in brown adipose tissue function and diet-induced
thermogenesis in HFD mice [38], JAK2 signaling between leptin and IFNγ may play a
critical role in obesity-related inflammation and metabolic disorders. Dimerized STAT3 acts
as a transcription factor and upregulates SOCS3 expression, which can induce hypothalamic
leptin resistance linked to obesity [39,40]. As we demonstrated previously, female AREDel-/- mice specifically induced SOCS3 gene expression in the liver, inhibition of which
correlates with the activation of alternative pathways, such as PI3K/AKT [41]. It has
also been reported that IFNγ induces SOCS3 expression, which further inhibits STAT3
phosphorylation in endothelial cells, implying that IFNγ can desensitize liver cells to leptin
signaling via the SOCS3-mediated inhibition of STAT3 [42]. Taken together, the signaling
interaction between leptin and IFNγ, particularly in adipose tissue of obese individuals,
may play a key modulating role in obesity-associated metabolic disorders and development
of pathology.
Here, we demonstrated a potential therapeutic effect of luteolin in the early pathogenic
development of PBC, as well as in other Th1-mediated autoimmune diseases. Luteolin
(30 ,40 ,5,7-tetrahydroxyflavone) has been thought to have beneficial anti-cancer, anti-oxidant,
and anti-inflammatory effects [43–45]. However, the mechanisms by which these beneficial
effects occur have not been elucidated. Luteolin inhibits antigen-specific IFNγ production
in autoreactive T cells in vitro [46], indicating that luteolin has a suppressive effect on IFNγ
production through the adaptive immune response. Our data support the suppressive role
luteolin in IFNγ signaling, but also reveal that luteolin can suppress early IFNγ-induced
innate immune responses, possibly via NR signaling, by particularly enhancing the PPAR
signaling pathway. Luteolin not only suppressed MHC I and II class antigen presentation
pathways, but also modulated FOA and Oxphos metabolic pathways, which are critical for
functional and phenotypical changes in macrophages. This luteolin-mediated metabolic
change may be a key regulatory mechanism to suppress early IFNγ-mediated inflammatory
reaction in the livers of HFD mice.
Additionally, these data demonstrate that immune network-based analysis can efficiently integrate different platforms or technologies that measure gene expression analysis.
Since RNA-sequencing emerged last decade as a more robust and reproducible analysis
tool than previous commonly used gene expression arrays [47], it has often been required to
compare gene expression profiles generated by these two different technologies. However,
comparison of differentially expressed genes (DEGs) identified in these different platforms
is not possible, as the datasets are incompatible with each other, even when generated from
the same biological condition. Given that immune responses are prompt, and gene sets
are simultaneously activated, immune network-based analysis can be consistent and inde-
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pendent of different gene expression analysis platforms. Therefore, this methodological
approach can be further used for the analysis of immune responses to compare mechanisms
as well as the drug repurposing. Immune network-based analysis, as shown here, was
used to predict the therapeutic effect of luteolin in the early stages of PBC pathogenesis.
4. Materials and Methods
4.1. Data Source
GSE76309 and GSE54189 datasets were obtained from the GEO database (http://
www.ncbi.nlm.nih.gov/geo/). In the GSE76309 dataset [6], mRNA was isolated from the
liver of ARE-Del-/- mice and analyzed by Illumina HiSeq2500 sequencing with TruSeq v4
chemistry. BAM files were generated by Tophat (v2.0.8), aligned to the mouse reference
genome mm9 and ensemble v70 transcripts. Each BAM file was uploaded into Partek
Genome Studio 6.6 to identify DEGs. The GSE54189 dataset [15] includes gene expression
profiles of adipose tissue and liver from C57BL/6 mice, the same genetic background as
ARE-Del-/- mice [24]. This dataset contains array-based gene expression analyses using
Illumina Mouse WG-6 v2 Expression BeadChips (Illumina, San Diego, CA, USA). Further
data analysis was performed with ArrayAssist software (Stratagene, La Jolla, CA, USA)
using Bioconductor.
4.2. Gene Set Enrichment and Pathway Analysis
Although GSEA and IPA are commonly used to characterize biological functions of
gene expression profiles, the difficulty lies in selecting the appropriate comparison dataset
and pathways from among an ever-increasing collection of datasets. As immune responses
are often dynamically regulated by posttranslational modification [48,49], knowledge-based
analysis is essential in order to characterize the immune network in human diseases as
performed in this research. For GSEA, we downloaded target gene sets from the Molecular
Signatures Database (MSigDB). The ranked experimental gene was listed along with the
enriched gene sets. For IPA, statistically significant DEGs were tested using knowledgebased datasets. Z-score, ratio, and p-value were calculated to define the significance of a
gene functioning in a network, as well as intergenic relationships. p-value was calculated
using the right-tailed Fisher’s exact test, and a p-value less than 0.05 signified statistical
significance and nonrandom association.
5. Conclusions
These data provide new insights into the mechanistic understanding of obesityassociated inflammatory responses in terms of the IFNγ signaling pathway and the etiological link to pathological development of PBC. Furthermore, we present a potential
therapeutic application of luteolin in the treatment of PBC, as well as other Th1-mediated
autoimmune diseases, based on comparison of similar immune responses.
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